GE Healthcare introduces new molecular imaging tools

GE Healthcare has showcased an array of new molecular imaging tools for use in drug development at an industry conference last week.

The medical device firm attended the World Molecular Imaging Congress to demonstrate new advances in fields such as pre-clinical imaging, PET radiopharmacy and PET/CT imaging.

Among them was Triumph II, a new tri-modality pre-clinical imaging system, and the integrated SPECT/CT system eXplore speCZT/CT120, while an enhanced version of the TRACERlab FX FN was also introduced.

The company also demonstrated its Discovery PET/CT 690, a molecular imaging device which allows for fast and high-quality performance and functioning.

Terri Bresenham, vice-president and general manager of GE Healthcare's molecular imaging business, said: "We are committed to providing researchers with the ability to produce tracers, one-touch point services and imaging equipment to discover and understand disease from the beginning."

Last week, GE Healthcare announced plans to work together with iBio and the Fraunhofer USA Center for Molecular Biotechnology in order to develop and market new manufacturing solutions for the pharmaceutical industry.